![]() ![]() ![]() “As part of Bio-Rad's continued growth in oncology and expansion into the field of molecular MRD monitoring, we are pleased that Biodesix is utilizing the advanced multiplexing QX600 ddPCR System that will be launching later this year," said Simon May, EVP & President, Life Science Group, Bio-Rad Laboratories. While the initial focus will be on developing a novel MRD test for solid tumors as an addition to our pipeline, Biodesix hopes to co-develop and validate a number of new test concepts under the agreement,” said Scott Hutton, CEO, Biodesix. “The initiation of this research program with MSK is a significant milestone for Biodesix. Bruker launched the Canopy CellScape, its latest ChipCytometry platform for spatial biology. The relatively compact system features a fully integrated droplet generator and four color reader, saving bench space. Initially, the teams will collaborate to develop a highly sensitive molecular MRD test on the new ddPCR platform, the Bio-Rad QX600 ddPCR System. Bio-Rad also displayed the QX1 dPCR platform, which has been on the market for a year. Biodesix will utilize its array of genomics, proteomics, artificial intelligence, and machine learning capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment.īiodesix also leverages the proprietary and advanced Diagnostic Cortex AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. The blood based Nodify Lung nodule risk assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. ![]() Additionally, in the future, MSK and Biodesix could also develop other diagnostic tests aimed at improving the treatment of cancer.īiodesix is the first company to offer eight non-invasive tests for patients with lung diseases. (Boulder, CO, USA) is developing a new novel minimal residual disease (MRD) test in association with the Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) that will utilize the advanced multiplexing QX600 ddPCR System to be launched by Bio-Rad Laboratories (Hercules, CA, USA) later this year. The QX600 Droplet Digital PCR System requires the use of the C1000 Touch Thermal Cycler with 96–Deep Well Reaction Module and the PX1 PCR Plate Sealer.Biodesix, Inc. Wastewater testing - Leverage the QX600 System to perform population-wide monitoring of established and emerging pathogens.Food testing - Use the QX600 System to perform routine evaluation of genetically modified organisms (GMO) and pathogen contamination detection.Cell and gene therapy - Accelerate therapeutics discovery with highly-advanced multiplexing afforded by the QX600 System.Next generation sequencing (NGS) orthogonal testing - With the QX600 System perform accurate quantification and qualification of NGS libraries without the use of a standard curves.Gene Expression - Employ the extreme precision of the QX600 System to quantify small-fold changes in low abundance RNA molecules.Oncology research - The QX600 System collects more information per well, preserving precious circulating tumor DNA (ctDNA) and tumor samples.The QX600 System enhances a wide variety of applications, including: oncology research, gene expression, next generation sequencing (NGS) orthogonal testing, cell and gene therapy, food and wastewater testing. System capable of running both TaqMan® and EvaGreen chemistriesĪpplications of the QX600 Droplet Digital PCR System.Extensive menu of pre-existing ddPCR assays.Cross-compatibility with QX200 reagents, assays, and consumables.Assay protocol files for automated data analysis and reporting with premium edition.FDA 21 CFR Part 11 compliance with premium edition Sets the standard for reproducibility as demonstrated in numerous studies.Confidence in your results bolstered by a system qualified by standards from National Measurement Institute (NMI), Australia.Sensitive and precise gene expression multiplexing.Absolute quantification with 0.1% or better sensitivity.Quantification of up to 12 targets in a single well.Six-color detection capability (FAM, HEX, Cy5, Cy5.5, ROX, and ATTO 590). ![]() Benefits of the QX600 Droplet Digital PCR System The QX600 Droplet Digital PCR System (ddPCR™) offers advanced six-color multiplexing and absolute quantification of nucleic acid, while delivering the best-in-class performance you have come to expect from Bio-Rad’s ddPCR systems. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |